IRVINE, Calif., Nov. 15 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC BB: CLBE), an emerging life sciences company (http://www.CalbaTech.com ) concentrating on providing products and platforms to the biotech and pharmaceutical research market and to academic institutions, today announced revenues for the nine months ended June 30, 2005 totaled $952,312, up from $128,940 for the same period in 2004. Revenues for the third quarter totaled $326,967, compared to revenues of $70,723 for the same period in 2004. The Company announced a gross profit of $650,817 for the first nine months of the fiscal year and $227,298 for the third quarter. "We believe that revenues will continue to increase significantly from operations in the coming year," said James DeOlden, CalbaTech Chairman and CEO. About CalbaTech CalbaTech, Inc. (OTC Bulletin Board: CLBE - News) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions. Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com Note: Certain statements in this news release may contain "forward-looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements. SOURCE CalbaTech, Inc.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
